The fund holds a concentrated portfolio of global companies in the biopharmaceutical and healthcare equipment and services industries that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering. In addition to these industry screens, companies must also meet certain size and liquidity measures for index eligibility. The underlying index then assigns a Relationship Keyword Score to each of the eligible companies using the FactSet Supply Chain Relationships database in search for keywords related to Genomics and Immuno Biopharmaceutical products and technologies. The top 50 names with the highest scores are included in the index. Holdings are weighted by market-cap and are constrained such that no individual security exceeds 4% weight of the portfolio. The index rebalances semi-annually.